Exenatide vs Semaglutide
Exenatide (GLP-1 receptor agonist)
The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class.
Semaglutide (GLP-1 receptor agonist)
A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
| Attribute | Exenatide | Semaglutide |
|---|---|---|
| Category | Metabolic | Metabolic |
| FDA status | FDA-approved (Byetta, Bydureon) | FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management) |
| Half-life | ~2.4 hours (immediate release) | ~7 days |
| Molecular weight | 4,186.6 Da | 4,113.6 Da |
| Mechanism | Agonizes the GLP-1 receptor with roughly 53% homology to human GLP-1, enhancing insulin secretion, reducing glucagon, and slowing gastric emptying. | Activates the GLP-1 receptor, increasing insulin secretion when glucose is elevated, suppressing glucagon, slowing gastric emptying, and acting on hypothalamic appetite centers to reduce food intake. |
| Legal status (US) | FDA-approved, prescription only | FDA-approved, prescription only |
Frequently asked questions
What is the difference between Exenatide and Semaglutide?
Exenatide: The first approved GLP-1 receptor agonist, derived from Gila monster venom, which established the entire drug class. Semaglutide: A long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management, with proven cardiovascular risk reduction.
Which has stronger research evidence, Exenatide or Semaglutide?
Exenatide is rated Strong and Semaglutide is rated Strong for evidence level in this database. Evidence level reflects the quality of published research, not a recommendation.
Are Exenatide and Semaglutide FDA-approved?
Exenatide: FDA-approved (Byetta, Bydureon). Semaglutide: FDA-approved (Ozempic, Rybelsus for T2D; Wegovy injection, Wegovy pill approved Dec 2025, and Wegovy HD 7.2 mg approved Mar 2026 for weight management).
Evidence levels reflect the quality of published research, not a recommendation. This comparison is educational and is not medical advice.